Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198237 · ClinicalTrials.gov registry record · Phase 2
Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00198237 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 40 participants.
The verdict
NCT00198237, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy \& toxicity of combined docetaxel \& capecitabine as primary chemo for subjects w/ stage II-III breast cancer.
Interventions
- DRUG docetaxel & capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198237
The ClinicalTrials.gov registry entry for NCT00198237 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel & capecitabine is the first listed.
NCT00198237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198237 about?
NCT00198237 is a clinical study titled "Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer". The primary objective of this study is to determine the efficacy \& toxicity of combined docetaxel \& capecitabine as primary chemo for subjects w/ stage II-III breast cancer.
What is the current status of trial NCT00198237?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2003-03. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00198237?
The interventions under investigation include: docetaxel & capecitabine (DRUG).
Who is sponsoring clinical trial NCT00198237?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.